-
Something wrong with this record ?
Clear cell mesotheliomas with inactivating VHL mutations and near-haploid genomic features
M. Michal, O. Kravtsov, JS. Ross, D. Skanderová, P. Martínek, E. Mosaieby, DA. Mata, EA. Williams, YP. Hung
Language English Country United States
Document type Systematic Review, Journal Article
PubMed
36515470
DOI
10.1002/gcc.23119
Knihovny.cz E-resources
- MeSH
- Chromosome Aberrations MeSH
- Genomics MeSH
- Haploidy MeSH
- Middle Aged MeSH
- Humans MeSH
- Mesothelioma, Malignant * MeSH
- Mesothelioma * genetics MeSH
- Mutation MeSH
- Von Hippel-Lindau Tumor Suppressor Protein genetics MeSH
- Lung Neoplasms * genetics MeSH
- Aged MeSH
- Ubiquitin Thiolesterase genetics MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Systematic Review MeSH
Clear cell mesothelioma is uncommon and shows predominance of clear cells with resemblance to clear cell carcinomas. Clinicopathologic and molecular descriptions of clear cell mesothelioma remained limited. In this study, we identified an index patient with clear cell mesothelioma, confirmed by immunohistochemical and ultrastructural studies. Targeted next-generation sequencing revealed the presence of an inactivating VHL mutation. We then systematically searched for VHL-mutant mesotheliomas in a comprehensive genomic profiling database of 1532 mesotheliomas. Collectively, we identified a cohort of four VHL-mutant clear cell mesotheliomas, including three peritoneal and one pleural tumors from three females and one male, with age range of 47-68 (median 63) years. Histologically, each tumor showed a microcystic to tubulopapillary architecture with prominent clear cells. By next-generation DNA sequencing, each of the four clear cell mesotheliomas harbored inactivating VHL mutations, while lacking other alterations typical of mesotheliomas such as BAP1, NF2, SETD2, CDKN2A, CDKN2B, TP53, and PTEN. By using low-pass whole genome sequencing on the index case and targeted next-generation sequencing on the remaining three cases, we identified extensive loss of heterozygosity throughout the genome but consistently sparing chromosomes 5, 7, and 20, characteristic of genomic near-haploidization. In summary, clear cell mesotheliomas were characterized by inactivating VHL mutations and genomic near-haploidization and appeared to represent a distinct clinicopathologic and molecular category of mesotheliomas. Our findings implicate VHL in the pathogenesis of a subset of mesotheliomas, particularly those with clear cell morphology.
Department of Pathology Bioptical Laboratory Ltd Plzen Czech Republic
Department of Pathology Faculty of Medicine in Plzen Charles University Plzen Czech Republic
Department of Pathology Foundation Medicine Inc Cambridge Massachusetts USA
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23003615
- 003
- CZ-PrNML
- 005
- 20230425140747.0
- 007
- ta
- 008
- 230418s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/gcc.23119 $2 doi
- 035 __
- $a (PubMed)36515470
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Michal, Michael $u Department of Pathology, Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic $u Department of Pathology, Bioptical Laboratory Ltd., Plzen, Czech Republic $1 https://orcid.org/0000000344037027
- 245 10
- $a Clear cell mesotheliomas with inactivating VHL mutations and near-haploid genomic features / $c M. Michal, O. Kravtsov, JS. Ross, D. Skanderová, P. Martínek, E. Mosaieby, DA. Mata, EA. Williams, YP. Hung
- 520 9_
- $a Clear cell mesothelioma is uncommon and shows predominance of clear cells with resemblance to clear cell carcinomas. Clinicopathologic and molecular descriptions of clear cell mesothelioma remained limited. In this study, we identified an index patient with clear cell mesothelioma, confirmed by immunohistochemical and ultrastructural studies. Targeted next-generation sequencing revealed the presence of an inactivating VHL mutation. We then systematically searched for VHL-mutant mesotheliomas in a comprehensive genomic profiling database of 1532 mesotheliomas. Collectively, we identified a cohort of four VHL-mutant clear cell mesotheliomas, including three peritoneal and one pleural tumors from three females and one male, with age range of 47-68 (median 63) years. Histologically, each tumor showed a microcystic to tubulopapillary architecture with prominent clear cells. By next-generation DNA sequencing, each of the four clear cell mesotheliomas harbored inactivating VHL mutations, while lacking other alterations typical of mesotheliomas such as BAP1, NF2, SETD2, CDKN2A, CDKN2B, TP53, and PTEN. By using low-pass whole genome sequencing on the index case and targeted next-generation sequencing on the remaining three cases, we identified extensive loss of heterozygosity throughout the genome but consistently sparing chromosomes 5, 7, and 20, characteristic of genomic near-haploidization. In summary, clear cell mesotheliomas were characterized by inactivating VHL mutations and genomic near-haploidization and appeared to represent a distinct clinicopathologic and molecular category of mesotheliomas. Our findings implicate VHL in the pathogenesis of a subset of mesotheliomas, particularly those with clear cell morphology.
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a haploidie $7 D006238
- 650 12
- $a nádory plic $x genetika $7 D008175
- 650 12
- $a mezoteliom $x genetika $7 D008654
- 650 12
- $a maligní mezoteliom $7 D000086002
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a chromozomální aberace $7 D002869
- 650 _2
- $a genomika $7 D023281
- 650 _2
- $a thiolesterasa ubikvitinu $x genetika $7 D043222
- 650 _2
- $a nádorový supresorový protein VHL $x genetika $7 D051794
- 655 _2
- $a systematický přehled $7 D000078182
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kravtsov, Oleksandr $u Department of Pathology, State University of New York Upstate Medical University, New York, New York, USA $1 https://orcid.org/0000000209971933
- 700 1_
- $a Ross, Jeffrey S $u Department of Pathology, State University of New York Upstate Medical University, New York, New York, USA $u Department of Pathology, Foundation Medicine, Inc., Cambridge, Massachusetts, USA
- 700 1_
- $a Skanderová, Daniela $u Department of Clinical and Molecular Pathology, Institute of Translational and Molecular Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
- 700 1_
- $a Martínek, Petr $u Department of Pathology, Bioptical Laboratory Ltd., Plzen, Czech Republic
- 700 1_
- $a Mosaieby, Elaheh $u Department of Pathology, Bioptical Laboratory Ltd., Plzen, Czech Republic
- 700 1_
- $a Mata, Douglas A $u Department of Pathology, Foundation Medicine, Inc., Cambridge, Massachusetts, USA $1 https://orcid.org/0000000280598668
- 700 1_
- $a Williams, Erik A $u Department of Pathology, Foundation Medicine, Inc., Cambridge, Massachusetts, USA $u Department of Pathology and Laboratory Medicine, Sylvester Comprehensive Cancer Center, and Jackson Memorial Hospitals, University of Miami, Miami, Florida, USA
- 700 1_
- $a Hung, Yin P $u Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA $1 https://orcid.org/0000000285681591
- 773 0_
- $w MED00001898 $t Genes, chromosomes & cancer $x 1098-2264 $g Roč. 62, č. 5 (2023), s. 267-274
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36515470 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425140743 $b ABA008
- 999 __
- $a ok $b bmc $g 1924349 $s 1189824
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 62 $c 5 $d 267-274 $e 20221225 $i 1098-2264 $m Genes, chromosomes & cancer $n Genes Chromosom Cancer $x MED00001898
- LZP __
- $a Pubmed-20230418